From Fibrosis Mechanisms to Medicine: 3D Spheroid Models of MASH for Translational Discovery

In this webinar, on Thursday, April 16, 2026, at 1 PM EDT, InSphero, together with Pharmanest and Icahn School of Medicine at Mount Sinai New York, will explore how emerging therapeutic strategies and enabling technologies are shaping the future of MASH treatment, focusing on the continued importance of anti-fibrotic approaches, advanced 3D human in vitro models, and AI-driven digital pathology.

GLP-1–based therapies are reshaping MASH treatment by effectively reducing weight and liver fat, but they do not eliminate the need for anti-fibrotic strategies. Fibrosis remains the strongest predictor of liver-related outcomes, and meaningful fibrosis regression is still harder to achieve than metabolic improvement. As a result, combination approaches are emerging as the next step, especially for patients with advanced disease or incomplete response.

In this evolving landscape, the key question is no longer whether we can reduce steatosis, but whether we can halt or reverse complex fibrotic remodeling, keeping anti-fibrotic drug development highly relevant.

To support this shift, more predictive preclinical tools are needed. Advanced 3D human in vitro models can better capture fibrosis biology, stellate cell activation, extracellular matrix deposition, and inflammatory crosstalk, while distinguishing true anti-fibrotic effects from metabolic changes. At the same time, digital pathology is becoming essential for robust fibrosis assessment, enabling more precise and quantitative evaluation of tissue remodeling.